The Genetic Engineering Information Bulletin: an independent, widely sourced digest of information relevant to the genetic engineering (GE) debate  
 
Home
  GE Info Bulletins  
   
  Return to Bulletin 42  
  Support  
 
No. 42 March 2006


EU: NO LICENCE FOR MEDICINE IN GM GOAT MILK

An application to licence the world's first medicine to be produced from a genetically modified (GM) animal was turned down by the European Medicines Agency (EMEA) on 24 February. GTC Biotherapeutics, a company based in the US, engineered goats to contain a human gene that codes for anti-thrombin, an anticoagulant. The result was goats that produce in their milk a substance that inhibits blood clots from forming. The medicine, called Atryn, would have been used by people with an inherited disease leaving them prone to developing blood clots. However, the EMEA decided that the company applying for the licence had failed to demonstrate the benefits of the drug outweighed its risks. EMEA said the testing process on patients giving birth or undergoing surgery was insufficient and not supportive. On the other side of the Atlantic, the US Food and Drug Administration (FDA) is continuing to consider a preliminary report that showed that meat and milk products from cloned farm animals and their offspring were as safe for human consumption as conventional animals, though a regulatory decision on food from cloned animals has been postponed for several months and is expected soon (see Bridges Trade BioRes, 24 June 2005, http://www.ictsd.org/biores/05-06-24/inbrief.htm#6). The World Organization for Animal Health (OIE) at its last General Session decided to undertake further investigations on the need for international standards on the use of animals that have been genetically engineered to produce medicines or chemicals (see Bridges TradeBioRes, 10 June 2005, http://www.ictsd.org/biores/05-06-10/story3.htm).

ICTSD Reporting; "'Pharmed' goat drug not approved," BBC NEWS, 24 February 2006; "'Pharmed" goats seek drug licence", BBC NEWS, 22 February 2006.

 

Web Link: http://www.ictsd.org/biores/06-03-03/inbrief.htm#5

Note that direct links to the source are provided wherever possible. Otherwise, a link to a web-posted copy on a 3rd party site is given.
Sometimes these links will expire, so the above archived copy will be the only reference.

** NOTICE: In accordance with Title 17 U.S.C. Section 107, this material is distributed for research and educational purposes only. **

 

   
 
 

From The GE Information Service
The items in this bulletin are from articles which remain the copyright of the original owners. The material is published here for educational and public interest use only.


Hard copies of the Bulletin are available.
Single issues can be purchased for $5. You can also take out an annual subscription, covering a minimum of 10 issues, for $35.


The GE Information Bulletin is a project of the GE Information Service. It presents a regular digest of significant information from an international range of sources.
We rely on donations, grants and sponsorship. Please support our work to promote informed debate regarding the responsible use of genetic engineering.
Supporters have no editorial influence.

 


The GE Information Service
PO Box 78121, Grey Lynn
Auckland, New Zealand

Editor:
Stuart Sontier
Email:
editor@GEinfo.org.nz